Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan

BACKGROUND AND OBJECTIVES: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. Recently, Tolvaptan has been introduced for the treatment of ADPKD, but whether it is associated with alterations of the u...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin J Am Soc Nephrol
Asıl Yazarlar: Bargagli, Matteo, Dhayat, Nasser A., Anderegg, Manuel, Semmo, Mariam, Huynh-Do, Uyen, Vogt, Bruno, Ferraro, Pietro Manuel, Fuster, Daniel G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Nephrology 2020
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341771/
https://ncbi.nlm.nih.gov/pubmed/32527945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.13861119
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller